XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenue (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2019
Revenue From Contract With Customer [Abstract] |
Composition of Total Revenue by Product and U.S versus Rest of World | The following tables present detail regarding the composition of the Company’s total revenue by product and U.S. versus rest of world, “RoW”:
|  | Three months ended March 31, |
|  | 2019 |  |  | 2018 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 114.3 |  |  | $ | 3.3 |  |  | $ | 117.6 |  |  | $ | 110.4 |  |  | $ | 2.7 |  |  | $ | 113.1 |
GeneSight |  |  | 29.6 |  |  |  | — |  |  |  | 29.6 |  |  |  | 30.4 |  |  |  | — |  |  |  | 30.4 |
Prenatal |  |  | 30.6 |  |  |  | — |  |  |  | 30.6 |  |  |  | — |  |  |  | — |  |  |  | — |
Vectra |  |  | 11.3 |  |  |  | — |  |  |  | 11.3 |  |  |  | 15.0 |  |  |  | — |  |  |  | 15.0 |
Prolaris |  |  | 6.9 |  |  |  | — |  |  |  | 6.9 |  |  |  | 6.3 |  |  |  | 0.1 |  |  |  | 6.4 |
EndoPredict |  |  | 0.5 |  |  |  | 2.3 |  |  |  | 2.8 |  |  |  | 0.2 |  |  |  | 2.1 |  |  |  | 2.3 |
Other |  |  | 1.5 |  |  |  | 0.2 |  |  |  | 1.7 |  |  |  | 2.0 |  |  |  | 0.1 |  |  |  | 2.1 |
Total molecular diagnostic revenue |  |  | 194.7 |  |  |  | 5.8 |  |  |  | 200.5 |  |  |  | 164.3 |  |  |  | 5.0 |  |  |  | 169.3 |
Pharmaceutical and clinical service revenue |  |  | 9.7 |  |  |  | 6.4 |  |  |  | 16.1 |  |  |  | 7.0 |  |  |  | 6.8 |  |  |  | 13.8 |
Total revenue |  | $ | 204.4 |  |  | $ | 12.2 |  |  | $ | 216.6 |  |  | $ | 171.3 |  |  | $ | 11.8 |  |  | $ | 183.1 |
|  | Nine months ended March 31, |
|  | 2019 |  |  | 2018 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 351.4 |  |  | $ | 9.3 |  |  | $ | 360.7 |  |  | $ | 344.5 |  |  | $ | 7.7 |  |  | $ | 352.2 |
GeneSight |  |  | 82.8 |  |  |  | — |  |  |  | 82.8 |  |  |  | 91.0 |  |  |  | — |  |  |  | 91.0 |
Prenatal |  |  | 80.0 |  |  |  | — |  |  |  | 80.0 |  |  |  | — |  |  |  | — |  |  |  | — |
Vectra |  |  | 36.1 |  |  |  | — |  |  |  | 36.1 |  |  |  | 40.1 |  |  |  | — |  |  |  | 40.1 |
Prolaris |  |  | 19.1 |  |  |  | 0.1 |  |  |  | 19.2 |  |  |  | 14.3 |  |  |  | 0.1 |  |  |  | 14.4 |
EndoPredict |  |  | 1.2 |  |  |  | 6.2 |  |  |  | 7.4 |  |  |  | 0.3 |  |  |  | 5.8 |  |  |  | 6.1 |
Other |  |  | 5.8 |  |  |  | 0.5 |  |  |  | 6.3 |  |  |  | 5.5 |  |  |  | 0.4 |  |  |  | 5.9 |
Total molecular diagnostic revenue |  |  | 576.4 |  |  |  | 16.1 |  |  |  | 592.5 |  |  |  | 495.7 |  |  |  | 14.0 |  |  |  | 509.7 |
Pharmaceutical and clinical service revenue |  |  | 25.5 |  |  |  | 17.7 |  |  |  | 43.2 |  |  |  | 22.3 |  |  |  | 17.8 |  |  |  | 40.1 |
Total revenue |  | $ | 601.9 |  |  | $ | 33.8 |  |  | $ | 635.7 |  |  | $ | 518.0 |  |  | $ | 31.8 |  |  | $ | 549.8 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
|  | Nine months ended |
|  | March 31, |
|  | 2019 |  |  | 2018 |
Deferred revenue - beginning balance |  | $ | 2.6 |  |  | $ | 2.6 |
Revenue recognized |  |  | (5.9 | ) |  |  | (13.8 | )
Prepayments |  |  | 5.6 |  |  |  | 13.8 |
Deferred revenue - Ending Balance |  | $ | 2.3 |  |  | $ | 2.6 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration